Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eragidomide in R/R AML and MDS
NCT02848001Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Nov 2016
- Primary completion
- Apr 2023
- Modality
- Molecular Glues
- Countries
- 6
01
Overview
Phase 1, open-label trial of eragidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Number of Participants With Dose Limiting Toxicity up to 42 days. Started Nov 2016; status: terminated.
02
Drugs
eragidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02848001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848001.